Prof Paul Richardson presented the DETERMINATIION trial at both ASCO and EHA, and the manuscript appeared at the same time in the New England Journal of Medicine.
In this study, newly diagnosed patients were randomized to RVD and transplant, or RVD without transplant. In both arms, patients received lenalidomide until progression.
Similar to the IFM 2009 study there was a significant improvement in progression-free survival (PFS) with transplant (67.5 months versus 46.2 months), but at this follow-up this did not translate into an overall survival benefit. The median progression-free survival among patients who received RVD plus ASCT was 20.2 months longer in the DETERMINATION trial than in the IFM 2009 trial (67.5 vs. 47.3 months), which indicates that lenalidomide until progression is an important strategy to prevent disease progression.